Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Cardiovascular Complications and Risk of Death in Sickle-cell Disease
source: Lancet
year: 2016
authors: Gladwin MT
summary/abstract:In sickle-cell disease, a point mutation in the β-globin chain causes haemoglobin to polymerise within erythrocytes during deoxygenation, altering red blood cell rheology and causing haemolysis. Improvements in health infrastructure, preventive care, and clinical treatments have reduced the morbidity and mortality of sickle-cell disease in developed countries. However, as these patients live longer, the chronic effects of sustained haemolytic anaemia and episodic vaso-occlusive events drive the development of end-organ complications. Cardiopulmonary organ dysfunction and chronic kidney injury have a large effect on morbidity and premature mortality, and typically accelerate in the second decade of life. These processes culminate in the development of pulmonary hypertension, left ventricular diastolic heart disease, dysrhythmia, and sudden death. In this Series paper, we review the mechanisms, clinical features, and epidemiology of major cardiovascular complications in patients with sickle-cell disease and discuss how screening and intervention could reduce their incidence.
organization: Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, Division of Pulmonary, Allergy and Critical Care Medicine; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USADOI: 10.1016/S0140-6736(16)00647-4
read more full text
+myBinderRelated Content
-
Mental Health Resources for Black, Indigenous and People of Color (BIPOC)In addition to COVID-19, recent events h...
-
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysisThe cell adhesion molecule P-selectin pl...
-
Individualized pain plans significantly reduce hospitalization in pediatric sickle cell patients with vaso-occlusive...Background: Vaso-occlusive crisis (VOC)...
-
Sickle cell trait may not contribute to stroke riskSickle cell trait may not be an ...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
Retinopathy and sickle cellhttps://www.youtube.com/watch?v=i1awYgHl...
-
Fighting Through Our Pain TV with Thomas J. Harrington MDhttps://www.youtube.com/watch?time_conti...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.